Applying our synthetic lethality expertise for better cancer therapies
Explore the J. Michael Bishop Institute of Cancer Research
Dr. Dun Yang
Founder
Executive Chair
Chief Scientific Strategy Officer
OUR MISSION
To translate MYC-SL into biomarker-guided cancer therapies with meaningful clinical outcomes.
OUR VISION
To make MYC-driven cancers tractable through MYC-SL and structural-control therapeutics.
OUR STRENGTHS
MYC Biology · Synthetic Lethality · Architectural Control
GUNS-DF · MIPS · DrugGPT
Context-Optimized Assets · Scaffold-Diversified MYC-SL Compounds · Shared Biomarker Framework
PUBLICATIONS
Seeking a lasting immune attack to thwart cancer
MYC drop: Synthetic lethal drugs are targeting a common cancer culprit
Cancer has a vast range of genetic and epigenetic variations. A one-size-fits-all therapy is unfeasible, and personalized treatments are advancing.
Important updates
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.